{"analyses":[{"ciLowerLimit":"0.7","ciPctValue":"95","ciUpperLimit":"2.1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".55","paramType":"Hazard Ratio (HR)","paramValue":"1.19","statisticalMethod":"Regression, Cox","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"description":"Administration of any systemic therapy other than the immunosuppressive agents used for initial treatment, because of persistent or progressive chronic graft-versus-host disease","groups":[{"description":"Patients receive oral mycophenolate mofetil 1000 mg twice daily.","id":"OG000","title":"Mycophenolate Mofetil"},{"description":"Patients receive oral placebo twice daily","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Open Label Systemic Treatment Because of Inadequate Response to Primary Therapy","type":"SECONDARY","unitOfMeasure":"participants"}